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The classical cascade of coagulation describes 
two converging enzymatic cascades that are 
triggered either by exposure of blood to a 
damaged vessel wall (the extrinsic pathway) or 
by blood-borne components of the vascular 
system (the intrinsic pathway). In fact, the ex-
trinsic coagulation pathway starts by the bind-
ing of FVII (plasma factor VII) to tissue factor 
(TF) produced by subendothelial cells. The re-
sulting complex activates FX (factor X), which 
leads to thrombin generation and, ultimately, 
initiates the process of fibrin formation (Davie 
and  Ratnoff,  1964;  MacFarlane,  1964).  In 
contrast, the intrinsic pathway is initiated by 
contact phase proteins, including the zymogens 
factor XII, factor XI, and prekallikrein, as well 
as the cofactor high molecular weight kinino-
gen (HK; Yarovaya et al., 2002). FXII under-
goes autoactivation when bound to polyanionic 
surfaces, generating activated factor XII by a 
conformational change (Silverberg et al., 1980; 
Tankersley and Finlayson, 1984). FXIIa then 
converts prekallikrein into kallikrein by cleav-
age of a single peptide bond. Once small amounts 
of kallikrein are formed, they catalyze the con-
version of surface-bound FXII into FXIIa, 
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Blood coagulation starts immediately after damage to the vascular endothelium. This 
system is essential for minimizing blood loss from an injured blood vessel but also contrib-
utes to vascular thrombosis. Although it has long been thought that the intrinsic coagula-
tion pathway is not important for clotting in vivo, recent data obtained with genetically 
altered mice indicate that contact phase proteins seem to be essential for thrombus forma-
tion. We show that recombinant Ixodes ricinus contact phase inhibitor (Ir-CPI), a Kunitz-
type protein expressed by the salivary glands of the tick Ixodes ricinus, specifically interacts 
with activated human contact phase factors (FXIIa, FXIa, and kallikrein) and prolongs the 
activated partial thromboplastin time (aPTT) in vitro. The effects of Ir-CPI were also exam-
ined in vivo using both venous and arterial thrombosis models. Intravenous administration 
of Ir-CPI in rats and mice caused a dose-dependent reduction in venous thrombus forma-
tion and revealed a defect in the formation of arterial occlusive thrombi. Moreover, mice 
injected with Ir-CPI are protected against collagen- and epinephrine-induced thromboem-
bolism. Remarkably, the effective antithrombotic dose of Ir-CPI did not promote bleeding or 
impair blood coagulation parameters. To conclude, our results show that a contact phase 
inhibitor is an effective and safe antithrombotic agent in vivo.
© 2009 Decrem et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e2382 Ir-CPI, A NOVEL ANTITHROMBOTIC FACTOR | Decrem et al.
Many blood-sucking ectoparasites synthesize substances 
to thwart the defense mechanisms of the hosts on which they 
feed (Ribeiro and Francischetti, 2003). Ticks, in particular, 
produce salivary substances capable of modulating the host 
immune responses and maintain blood in a sufficiently fluid 
state to effectively acquire and digest their blood meal (Brossard 
and Wikel, 2004). As indicated earlier, hemostasis involves a 
network of factors organized in different pathways that can 
be activated independently. Ticks are, therefore, confronted 
with a redundant system and must simultaneously block sev-
eral different steps to obtain effective antihemostasis. This has 
been achieved during the long tick–host coevolution, as ticks 
produce a variety of compounds with antihemostatic activity 
(Ribeiro and Francischetti, 2003; Brossard and Wikel, 2004; 
Steen et al., 2006).
In this study, we characterize a novel serine protease 
inhibitor from the tick Ixodes ricinus. This protein, Ixodes ricinus 
contact phase inhibitor (Ir-CPI), has one Kunitz domain and 
is capable of effectively inhibiting the intrinsic coagulation 
pathway and, to a much lesser extent, fibrinolysis in vitro. 
We also showed that Ir-CPI can inhibit the reciprocal activa-
tion of FXII, prekallikrein, and FXI in human plasma by spe-
cifically binding to these three factors when they are activated. 
Lastly, tests in animal models showed that Ir-CPI has anti-
thrombotic properties in vivo and inhibits the formation of 
both venous and arterial thrombi without disturbing the clot-
ting balance. To our knowledge, this is the first time that a 
selective inhibitor of the coagulation contact phase has been 
shown to protect against the formation of both venous and 
arterial thrombi.
RESULTS
Sequence analysis of Seq7
Expression and purification of recombinant Seq7. To identify 
complementary DNAs (cDNAs) coding for proteins specifi-
cally expressed in the salivary glands of female I. ricinus ticks, 
a subtractive cDNA library was set up using messenger RNAs 
extracted from salivary glands of unfed and 5-d-fed female 
I. ricinus ticks (Leboulle et al., 2002). One clone, formerly called 
seq7 (GenBank accession no. AJ269641), was selected for fur-
ther characterization as it coded for a predicted protein (Seq7) 
with similarities to the second Kunitz domain of human TF 
pathway inhibitor. The predicted Seq7 amino acid sequence 
comprised the typical consensus Kunitz motif F-x(3)-G-C-
x(6)-[FY]-x(5)-C. Moreover, SignalP and TargetP programs 
predicted a signal peptide cleavage site at position 23 and the 
absence of a hydrophobic transmembrane region, suggesting 
that the protein was secreted.
To produce a recombinant form of Seq7, the open read-
ing frame deleted from the sequence predicted to code for a 
signal peptide was cloned in the expression vector pGEX-6P-1 
in frame with the coding sequence of glutathione S-transfer-
ase (GST) and expressed in bacteria. Affinity purification fol-
lowed by cleavage with PreScission protease and further fast 
protein liquid chromatography yielded pure recombinant 
protein (unpublished data).
leading to strong positive feedback on the system (Cochrane 
et al., 1973; Dunn et al., 1982). During this process, FXII is 
activated by a succession of proteolysis steps leading to the 
production of a series of different active enzymes: FXIIa 
and FXIIf (Kaplan and Austen, 1971; Revak et al., 1977; 
Silverberg et al., 1980; Dunn and Kaplan, 1982). In vitro, 
the  contact  phase  system  initiates  the  intrinsic  coagulation 
pathway by cleavage of FXI into activated factor XI by FXIIa 
(Bouma and Griffin, 1977; Kurachi and Davie, 1977). FXIIf 
may also activate FVII, the proenzyme initiating the extrin-
sic coagulation pathway (Kisiel et al., 1977; Radcliffe et al., 
1977). Propagation of clotting involves several positive-
feedback mechanisms. For example, thrombin can activate 
FXI, which activates additional factor IX, therefore amplify-
ing the coagulation process (von dem Borne et al., 1995). The 
surface-associated FVIIa–TF complex can activate FIX in 
addition to FX. This activation loop provides an impor-
tant contribution to the blood clotting process (Josso and 
Prou-Wartelle,  1965;  Osterud  and  Rapaport,  1977;  Bauer   
et al., 1990). It later became clear that activation of the con-
tact–phase system is critically involved in proteolytic mecha-
nisms distinct from coagulation, namely the kallikrein–kinin, 
complement, and fibrinolytic systems (Mandle and Kaplan, 
1979; Ghebrehiwet et al., 1983; Kaplan et al., 2002; Moreau 
et al., 2005).
The search for new anticoagulants is a major challenge in 
medicine. In practice, this involves identifying drugs capable 
of  preventing  thrombus  formation  without  increasing  the 
risk of hemorrhage. For the past 40 yr, anticoagulant treat-
ment has been dominated by two classes of agents: heparins 
and antivitamins K. Heparins accelerate the inhibitory action 
of antithrombin on some activated coagulation factors (spe-
cifically FXa and thrombin) by indirect inhibition of these 
factors and are only active when administered parenterally. 
The latter prevent the final synthesis of four coagulation fac-
tors (prothrombin, FVII, FIX, and FX). These compounds 
require careful laboratory testing to guarantee sufficient anti-
thrombotic effectiveness while avoiding the risk of hemor-
rhage. This disadvantage, together with the relatively narrow 
therapeutic margin of these drugs, has considerably stimulated 
research into other types of agents. The choice of anticoagu-
lant therapy, either for venous thromboembolism or arterial 
thrombosis (myocardial infarction or stroke), is based on how 
well a drug inhibits thrombosis and its hemorrhagic side 
effects. The recent discovery that FXI and FXII deficiency 
protects against thrombosis without causing spontaneous bleed-
ing in mice makes FXII a unique and ideal target for drug 
design (Gailani and Renné, 2007; Renné and Gailani, 2007). 
Indeed, FXII-deficient mice were found to be protected 
against arterial thrombosis, collagen- and epinephrine-induced 
thromboembolism (Renné et al., 2005), and ischemic brain 
stroke (Kleinschnitz et al., 2006). In all these models, the pro-
tection was abolished by the infusion of human FXII into 
FXII-null mice. Moreover, as in the case of their human coun-
terparts, the FXII-null mice do not suffer from impaired 
hemostasis (Pauer et al., 2004).JEM VOL. 206, October 26, 2009 
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to these results, Seq7 was renamed Ir-CPI (Ixodes ricinus con-
tact phase inhibitor).
Ir-CPI inhibits thrombin generation
As thrombin is the key player in clot formation, the effects of 
Ir-CPI were investigated on its activity during the coagula-
tion process. The intrinsic coagulation pathway was induced 
using a mixture of ellagic acid and phospholipid (PLs) as trig-
gers. The addition of recombinant Ir-CPI to the assay caused 
a dose-dependent prolongation of the lag time and a dose-
dependent decrease in the peak concentration of active throm-
bin (Cmax) compared with the control curve (i.e., without 
inhibitor; Fig. 2 A). At a final Ir-CPI concentration of   
9.1 µM, the lag time was prolonged 3.6-fold compared with 
the control curve. Regarding Cmax, the effect was maximal 
at 0.7 µM and did not increase at higher concentrations 
(2.2 µM, 6.6 µM, and 9.1 µM). At a concentration of 0.7 µM, 
Recombinant Ir-CPI prolongs activated partial throm-
boplastin time (aPTT) and fibrinolysis time. As Seq7 dis-
played homology to a factor involved in hemostasis, the 
activity of the recombinant protein was first assessed using 
classical global hemostasis tests in vitro. The recombinant 
protein had no effect on PFA closure time or platelet aggre-
gation with whole blood (unpublished data). This suggested 
that Seq7 did not interfere with primary hemostasis. The anti-
coagulant activity of Seq7 was then assessed using four rou-
tine tests of plasma clotting time. Prothrombin, thrombin, 
and  RVV  times  remained  unchanged  (unpublished  data), 
suggesting that Seq7 did not interfere with extrinsic or com-
mon factors of the coagulation cascade. However, recombinant 
Seq7 prolonged aPTT (7.7 times at 2 µM) in a dose-dependent 
manner (Fig. 1 A), showing interference with the intrinsic 
pathway. Finally, the activity of Seq7 was investigated on fi-
brinolysis. The results showed that the fibrinolysis time was 
slightly increased by 1.18-fold in the presence of Seq7 at 
2 µM (Fig. 1 B). All these experiments were also performed 
with GST used as a negative control. No interference was 
observed with any of the tests (unpublished data). According 
Figure 1.  In vitro anticoagulant activity of Ir-CPI. Increasing 
amounts of Ir-CPI were incubated with human plasma for 2 min. Coagu-
lation aPTT (A) and clot lysis times (B) were determined as described in 
Materials and methods. Each point represents the mean ± SEM of three 
independent determinations.
Figure 2.  Effect of Ir-CPI on the thrombin activity profile during 
the coagulation process induced either by intrinsic or extrinsic  
coagulation pathway. (A) Human plasma was incubated with various 
concentrations of Ir-CPI (0, 0.001, 0.003, 0.009, 0.027, 0.081, 0.243, 0.729, 
2.187, 6.561, and 9.077 µM), and the mixture was activated with ellagic 
acid and PL to initiate the intrinsic coagulation pathway. (B) Human 
plasma was incubated with various concentrations of Ir-CPI (0, 0.729, 
2.187, 6.561, and 9.077 µM), and the mixture was activated with 5 pM  
TF and PL to initiate the extrinsic coagulation pathway. The amidolytic activ-
ity of thrombin was determined by adding its specific fluorogenic sub-
strate and recording the increase in fluorescent signal. Results are 
presented as the mean of three independent experiments.2384 Ir-CPI, A NOVEL ANTITHROMBOTIC FACTOR | Decrem et al.
factors and their specific chromogenic substrates. In each of 
these assays, we compared the activation of a nonactivated 
factor (zymogen) by an activated factor in the presence or ab-
sence of Ir-CPI. The results showed that Ir-CPI inhibited the 
activation of prekallikrein into kallikrein by FXIIa, activation 
of FXI into FXIa by FXIIa, and activation of FXII into FXIIa 
by FXIa (Fig. 3, B–D). In contrast, Ir-CPI failed to inhibit the 
activation of FXII into FXIIa by kallikrein (unpublished data). 
Collectively, the results of these experiments show that 
Ir-CPI impacts the activation of some factors (e.g., FXIa and 
FXIIa) participating in the contact phase of coagulation.
Ir-CPI binds to FXIa, FXIIa, kallikrein, and plasmin
We then asked whether the inhibitory activity of Ir-CPI in-
volved a direct interaction with one or more blood coagulation 
factors by evaluating the capacity of Ir-CPI to bind to coagula-
tion or fibrinolysis factors or cofactors by surface plasmon reso-
nance. The assays demonstrated a specific interaction between 
Ir-CPI and four factors: FXIIa, FXIa, plasmin, and kallikrein 
(Fig. 4). No interaction was observed with any of the other 
factors or cofactors tested (prekallikrein, HK, FXII, FXI, FIX, 
FIXa, FX, FXa, prothrombin, thrombin, FVIIa, t-PA, and plas-
minogen; unpublished data). Except for kallikrein, these data 
were confirmed by using dot blot assays (Fig. S1). Moreover, 
the kinetics of interaction between Ir-CPI and the four targeted 
factors (FXIIa, FXIa, plasmin, and kallikrein) were measured 
after immobilization of Ir-CPI. In assays designed to determine 
the binding kinetics, the quantity of immobilized Ir-CPI was 
deliberately kept at a low level (200 resonance units [RU]) 
to avoid problems caused by limitation of the reaction rate by 
a mass-transport effect. The initial binding rate was shown to 
the Cmax was reduced by 37% and the lag time was pro-
longed 2.7-fold.
In contrast, when the coagulation cascade was triggered by 
the extrinsic pathway (5 pM TF and 4 µM PL), a slight dose-
dependent decrease in Cmax and a dose-dependent prolonga-
tion of the lag time were observed (Fig. 2 B). At a final Ir-CPI 
concentration of 9.1 µM, the Cmax was reduced by 30% and 
the lag time was prolonged 1.6-fold. Similar results were ob-
tained when a lower concentration of TF (1 pM) and PL (4 µM) 
were used as triggers. Overall, these results show that Ir-CPI 
is an inhibitor of thrombin generation.
Ir-CPI inhibits the activation of contact system factors
To determine the targets of Ir-CPI, its effect on seven proco-
agulant active serine proteases (namely kallikrein, FXIIa, FXIa, 
FIXa, FXa, FIIa, and FVIIa) and two fibrinolytic serine pro-
teases (tissue plasminogen activator [t-PA] and plasmin) was 
measured in amidolytic tests using specific substrates for each 
of these serine proteases. These assays failed to reveal any ef-
fect of the Ir-CPI protein on the amidolytic activity of these 
factors (unpublished data).
The capacity of Ir-CPI protein to inhibit the activation of 
these factors was then analyzed on human plasma contact 
phase factors by incubating human plasma with Ir-CPI and 
then adding a contact phase activator. The activation of con-
tact factors (FXII, FXI, and kallikrein) was evaluated using a 
specific substrate for each factor. The results showed that 
Ir-CPI inhibited the generation of the active form of these 
three factors in a dose-dependent manner (Fig. 3 A).
The effect of Ir-CPI on contact phase factors was further 
dissected and examined in reconstituted systems using purified 
Figure 3.  Inhibitory effect of Ir-CPI on generation of FXIIa, FXIa, and kallikrein in human plasma and on reconstituted systems. (A) Diluted 
human plasma was incubated with various concentrations of Ir-CPI (0.0625, 0.125, 0.25, 0.5, and 1 µM), and the mixture was activated with aPTT reagent 
to initiate the contact system. The amidolytic activities of generated FXIIa, FXIa, and kallikrein were determined by adding their specific chromogenic sub-
strates and recording the increase in absorbance at 405 nm. (B–D) The effect of Ir-CPI was examined in reconstituted systems using purified factors and 
their specific chromogenic substrates. The activation of a nonactivated factor by an activated factor, in the presence or absence of Ir-CPI, was analyzed in 
each experiment. (B) Activation of prekallikrein into kallikrein by FXIIa. (C) Activation of FXI into FXIa by FXIIa. (D) Activation of FXII into FXIIa by FXIa 
Results are presented as the mean ± SEM of three independent determinations.JEM VOL. 206, October 26, 2009 
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mation of AB, and ka2 and kd2 the forward and backward rate 
constants for the AB↔(AB) conformation change. The values 
of these rate constants are shown in Table I. These results in-
dicate that Ir-CPI specifically binds to FXIIa, FXIa, kallikrein, 
and plasmin but not to their zymogenic forms (Fig. 4). It 
should, however, be noted that the values in Table I are only 
indicative of the orders of magnitude. Indeed, large variations 
of the constants are observed when the association curves 
(Fig. 5, 0–84 s) are analyzed individually. Similarly, when the 
dissociation curves are fitted to a sum of two exponentials 
(y = yf + Ae-kt + Be-kt, where t is the time and k and k are 
complex functions of ka1, ka2, kd1, and kd2), the best fits are 
obtained with nonzero values of yf. This indicates that, with 
two exponentials, dissociation is not complete when time 
increases, which suggests a third, irreversible or very slowly 
reversible, step after the AB ↔(AB) conformation change. This 
irreversible component represents 20–40% for kallikrein,   
53–60% for fXIa, 10–24% for fXIIa, and 19–27% for plasmin.
be independent of flow variations by linear regression measure-
ments at the start of kinetics with injections of analytes at in-
creasing flows from 30 to 70 µl/min. This confirmed that there 
was no limitation of the reaction (unpublished data). Interaction 
kinetics were determined for each analyte at six different con-
centrations (from 5 to 300 nM). The data were processed with 
the BIA evaluation software and the best fits obtained with the 
following two-state binding model, which implies the binding 
of the plasma protein to immobilized Ir-CPI in a 1/1 ratio fol-
lowed by a reversible conformation change:
	 A B AB AB
k
k
k
k
d
a
d
a
+ ↔ ↔
1
1
2
2
( ) ,	
where A is the plasma protein, B is the immobilized Ir-
CPI,  and  (AB)  is  the  complex  form  after  conformational 
change in the initial complex AB. In this model, ka1 and kd1 
are the association and dissociation rate constants for the for-
Figure 4.  Sensorgrams for interactions between targeted factors (kallikrein, FXIa, FXIIa, and plasmin) and immobilized Ir-CPI measured by 
surface plasmon resonance. Ir-CPI was immobilized on the surface of a CM5 sensor chip at a level of 200 RU. Factors (from 5 to 300 nM) were injected 
at a flow rate of 70 µl/min in HBS buffer, and association was monitored for 84 s. After return to buffer flow, dissociation was monitored for 150 s. The 
sensor chip surface was regenerated by a pulse injection of 25 mM NaOH after each experiment. For each interaction, one representative result from 
three independent determinations is shown.
Table I.  Kinetic constants for Ir-CPI interactions with kallikrein, FXIa, FXIIa, and plasmin
Ir-CPI–targeted factors ka1 (1/Ms) kd1 (1/s) ka2 (1/s) kd2 (1/s) K (1/M)
Kallikrein 3.49 ± 0.54 × 104 5.32 ± 0.92 × 102 8.34 ± 0.07 × 103 1.42 ± 0.11 × 103 4.51 ± 0.19 × 106
FXIa 2.31 ± 0.59 × 106 1.02 ± 0.51 × 101 2.98 ± 0.29 × 102 2.32 ± 0.28 × 103 3.83 ± 2.37 × 108
FXIIa 2.19 ± 0.06 × 105 9.46 ± 0.04 × 102 6.55 ± 0.66 × 101 1.05 ± 0.04 × 101 1.68 ± 1.10 × 108
Plasmin 9.00 ± 0.39 × 105 5.35 ± 1.33 × 103 5.82 ± 0.99 × 103 6.14 ± 0.96 × 103 3.30 ± 0.57 × 108
Data represent the mean ± SD of three experiments.2386 Ir-CPI, A NOVEL ANTITHROMBOTIC FACTOR | Decrem et al.
were 40.8 ± 9.9% of the maximum value 20 h after i.v. ad-
ministration of the recombinant protein (unpublished data). 
The anticoagulant effect of Ir-CPI was also investigated with 
plasma from rats and mice. The results showed that Ir-CPI 
prolongs both the rat and the mouse aPTT by 2.18- and 
2.77-fold at 2 µM, respectively.
The antithrombotic in vivo action of Ir-CPI was first 
evaluated in a mouse model of lethal pulmonary thrombo-
embolism, induced by the infusion of a mixture of collagen 
and epinephrine. All vehicle mice (15 out of 15) died within 
5 min, with a dramatic reduction in circulating platelet counts 
within 2 min of the challenge (Fig. 5, A and B). In contrast, 
the two groups of Ir-CPI–treated mice showed a significant 
increase of survivors (3 out of 15 [20%] at 1 mg/kg Ir-CPI 
and 4 out 15 [26.7%] at 10 mg/kg Ir-CPI), although their 
peripheral platelet counts were reduced to a similar degree as 
those of mice injected with PBS. This suggests that the pro-
tection conferred by Ir-CPI administration is not caused by a 
platelet adhesion/activation defect but by a defect in throm-
bin generation or some other FXIIa/FXIa-related activity. 
Consistent with this premise, the analysis of the effect of   
Ir-CPI on primary hemostasis by using plasma and total blood 
from Ir-CPI–treated mice demonstrated no effect of Ir-CPI 
on platelet aggregation (unpublished data). In addition, the 
examination of histological sections of lung tissue showed a 
reduction in the number of occluded vessels in Ir-CPI–treated 
mice (survivors and nonsurvivors), whereas the majority of 
vessels were obstructed in vehicle (Fig. 5 C).
The effect of Ir-CPI on venous thrombus formation was 
then assessed using two thrombosis animal models. In the first 
model in rats, venous thrombosis was induced by stasis after 
vessel ligation and activation of thrombosis by severe endo-
thelial damage and vessel occlusion with ferric chloride (see 
Materials and methods). The control group showed 100% 
thrombus formation, with a mean thrombus weight of 19.6 ± 
1.6 mg/kg (n = 6). In contrast, prior i.v. administration of 
Ir-CPI induced a dose-dependent progressive decrease in 
thrombus formation, with a calculated effective concentra-
tion (EC50) at 49.2 µg/kg and with a maximum effect starting 
at 100 µg/kg (Fig. 6 A).
The efficacy of Ir-CPI in inhibiting thrombus formation 
was also measured on a murine model of venous thrombosis 
in which complete stasis is induced by ligation of the inferior 
vena cava (IVC). 5 min before surgery, mice were given an 
i.v. injection of either Ir-CPI (1 or 10 mg/kg) or the vehicle 
(PBS) in the caudal vein. Mice were sacrificed 24 h after 
thrombosis induction and the thrombosed IVC fragments 
were harvested and weighed. The clot weight/body weight 
ratio was significantly reduced in the presence of Ir-CPI, 
from 0.70 ± 0.11 in the control group to 0.24 ± 0.06 in the 
group of mice treated preventively with Ir-CPI at a dose of 
1 mg/kg (Fig. 6 B). Moreover, the clot weight/clot length 
ratio was 2.83 ± 0.54 for a thrombus formed in the control 
group, whereas it was only 1.86 ± 0.13 in mice treated with a 
dose of 1 mg/kg of Ir-CPI (Fig. 6 C). At a dose of 10 mg/kg 
of Ir-CPI, the clot weight/body weight and the clot weight/
Ir-CPI interferes with thrombus formation in animal models 
of venous thrombosis
Before testing the antithrombotic action of Ir-CPI, we evalu-
ated the half-life of Ir-CPI in vivo. A semiquantitative estimate 
of Ir-CPI pharmacokinetics was obtained using 125I-Ir-CPI. 
The results showed that plasma  125I-Ir-CPI concentrations 
Figure 5.  Effect of Ir-CPI on pulmonary embolism model. (A) Mor-
tality associated with i.v. of collagen and epinephrine after administration 
of PBS (vehicle) or Ir-CPI. All PBS-treated mice died within 5 min. Animals 
alive 30 min after the challenge were considered survivors. Data represent 
the mean ± SEM of the results obtained with 15 animals per group from 
two independent experiments. *, P ≤ 0.05. (B) Platelet counts in mice  
2 min after infusion of collagen/epinephrine. The control group was not 
injected with collagen/epinephrine. Data represents the mean ± SEM of 
results obtained with five animals per group from two independent ex-
periments. Values on the number of circulating platelets in the three 
groups of injected mice are significantly alike. (C) Number of thrombi in 
the lungs of mice 2 min after infusion of collagen/epinephrine. Thrombi 
per visual field were counted at 20×. Data represent the mean for  
20 fields per mice (n = 3 per group) from two independent experiments.JEM VOL. 206, October 26, 2009 
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of the blood vessels. Thrombus generation in 1-mg/kg Ir-CPI–
treated and untreated mice was initiated by i.v. injection of 
10 mg/kg of rose bengal followed by 20 s of high light inten-
sity exposition. In control mice, thrombus formation could 
be observed as soon as 30 min after light excitation and, 2 h 
later, blood flow was reduced or stopped in the major part of 
the chamber. However, in Ir-CPI–treated mice, no changes 
in the arterioles’ aspect or flow could be recorded after 2 h 
(Fig. 7 A) or after 24 h (not depicted). Fluorescent micros-
copy confirmed these results (Videos 1–4) and provided   
additional flow velocity data with help of Cap Image, a com-
puter-assisted image analysis program. Because flow velocity 
is not the same in each arteriole, results were expressed as 
a percentage of their own flow recorded before thrombus 
induction. Fig. 7 B shows an 86.2 ± 4.7% flow reduction in 
the control mice, whereas, in Ir-CPI-treated mice, the flow 
velocity remained unchanged.
DISCUSSION
Most of the antihemostatic mechanisms used by hematophagous 
parasites have evolved as adaptations to evade the vertebrate 
blood coagulation system (Mans et al., 2002). The importance of 
this selection pressure is illustrated by the wide range of strategies 
developed by these ectoparasites, enabling them to thwart 
primary hemostasis, clotting, and fibrinolysis during feeding 
(Ribeiro and Francischetti, 2003). Ticks are obligate hematoph-
agous ectoparasites and, when they feed, their mouthparts cause 
extensive damage to the tissues surrounding the bite site as they 
break the vessels locally and establish a nutrition cavity rich in 
cells and host blood factors. These factors must, therefore, be 
inhibited if ticks are to accomplish their blood meal.
In  vitro  experiments  showed  that  Ir-CPI  considerably 
prolongs the aPTT (7.7-fold at 2.0 µM), which measures the 
intrinsic pathway of coagulation, without modifying the PT, 
which measures the extrinsic pathway, the thrombin time, 
which measures the conversion of fibrinogen to fibrin and its 
subsequent polymerization, or the RVV time, which mea-
sures the activation of FX into FXa and the subsequent 
coagulation steps. Coagulation contact phase factors may, 
therefore, be the targets of Ir-CPI. Surface plasmon reso-
nance analysis and dot blot assays showed that Ir-CPI specifi-
cally binds to factors of the contact phase (namely, FXII, FXI, 
and kallikrein) but not to factors belonging to the common 
and TF pathways. In addition, Ir-CPI binds with a very high 
clot length ratios reached 0.15 ± 0.11 and 1.60 ± 0.33, respec-
tively. We also performed time-course experiments of clot 
formation in untreated and Ir-CPI treated mice. In Ir-CPI 
1 mg/kg-treated mice, the clot weight/body weight ratio and 
the clot weight/clot length ratio were significantly lower than 
in untreated mice after 6, 16, and 24 h stasis, whereas no dif-
ference was observed after 2 and 4 h. (Fig. 6, D and E).
To examine the effect of Ir-CPI on blood coagulation 
parameters after i.v. administration, the effects of Ir-CPI were 
then tested on ex vivo clotting assays. For the rats, Table II 
shows that aPTT values were similar in comparison with con-
trols for Ir-CPI EC50 and 100-µg/kg doses, whereas aPTT 
values were statistically higher in comparison with controls for 
Ir-CPI doses >1 mg/kg, showing a 1.4-fold increase in the 
latter case. In contrast, prothrombin time (PT) was not af-
fected by 1 mg/kg Ir-CPI. Moreover, this high dose of Ir-CPI 
had no effect on the fibrinolysis time (Table II). Finally, the 
bleeding effect of Ir-CPI was evaluated using a tail-transection 
model. No statistically significant blood loss was observed   
5 min after administration of 1 mg/kg Ir-CPI (Table II).
The effects of Ir-CPI in mice on ex vivo clotting assays 
were also tested. These showed that Ir-CPI at a dose of 1 mg/kg 
did not modify aPTT, PT, and fibrinolysis times. However, 
aPTT was increased in the presence of Ir-CPI at a dose of 
10 mg/kg (21.7 ± 2.4 in the control group vs. 39.8 ± 5.2 in 
the group of Ir-CPI–treated mice), whereas PT and fibrino-
lysis times remain unchanged at this dose. Finally, the bleeding 
effect of Ir-CPI was also evaluated by using a tail-transection 
model. In this case, the bleeding time was not affected after 
administration of 1 mg/kg Ir-CPI. Although we observed a 
slight increased of the bleeding time at a dose of 10 mg/kg, 
this value was not significant as compared with those obtained 
with untreated mice (Table III). Taken as a whole, these re-
sults show that Ir-CPI has a significant antithrombotic effect 
in vivo without increasing bleeding or impairing blood coag-
ulation parameters.
Ir-CPI interferes with thrombus formation in mouse arterial 
thrombosis model.
To further investigate the antithrombotic in vivo effect of 
Ir-CPI on arterial thrombosis, we performed intravital video-
microscopy, using a skinfold chamber model in which a 
transparent window is surgically placed into the dorsal skin of 
NMRI mice to allow direct visualization and light excitation 
Table II.  Hemostasis and coagulation in Ir-CPI–treated rats
Inhibitors aPTT PT Fibrinolysis Bleeding effect (O.D. 450 nm)
s s min
PBS 20.0 ± 3.8 21.4 ± 1.5 53 ± 27 0.026 ± 0.006
Ir-CPI 0.1 mg/kg 20.7 ± 3.9 21.3 ± 1.1 66 ± 29 0.067 ± 0.060
Ir-CPI 1 mg/kg 28.8 ± 3.4a 21.6 ± 1.6 51 ± 28 0.021 ± 0.008
LMWH 0.5 mg/kg 36.2 ± 3.8a 26.9 ± 1.4a 57 ± 19 0.174 ± 0.091a
Values are mean ± SEM (n = 5 for each test). LMWH, low molecular weight heparin.
aP < 0.05, as compared to values observed in the control (PBS) by one-way ANOVA and Student’s t test–Newman-Keuls test.2388 Ir-CPI, A NOVEL ANTITHROMBOTIC FACTOR | Decrem et al.
block the amidolytic activity of target proteases by binding 
the amino acid P1 of the inhibitors to the catalytic site of the 
enzyme (Laskowski and Kato, 1980). On the contrary, our 
results suggest that Ir-CPI does not directly interact with the 
site responsible for the amidolytic activity of FXIIa, FXIa, 
and kallikrein but probably acts on these factors by binding to 
an exosite, thereby preventing enzyme activity by steric hin-
drance. This action mechanism seems to be similar to that of 
two other anticoagulant factors: the Ixolaris protein, which is 
isolated from the tick I. scapularis (Francischetti et al., 2002), 
and bothrojaracin, which is isolated from the venom of the 
Brazilian snake jararaca (Zingali et al., 1993).
By binding to FXIIa, Ir-CPI prevents both activation of 
FXI into FXIa and activation of prekallikrein into kallikrein. 
affinity (Table I) to the activated form of the target enzymes 
and does not bind to the zymogenic form. This indicates that 
Ir-CPI does not block the activation of the target factor but, 
rather its action on the next factor in the clotting cascade. 
This was confirmed by showing that recombinant Ir-CPI 
protein inhibits the reciprocal activation of FXI, FXII, and 
prekallikrein in human plasma in a dose-dependent manner. 
Furthermore, Ir-CPI inhibits activation of these three factors 
in reconstituted systems (activation of a zymogen factor by an 
activated factor, activation of prekallikrein into kallikrein by 
FXIIa, and activation of FXI into FXIa by FXIIa) without 
affecting the amidolytic activity of these proteases. This was 
unexpected, as inhibitors belonging to the Kunitz-type serine 
protease inhibitor family (e.g., BPTI and TFPI) generally 
Figure 6.  Effect of Ir-CPI on venous thrombosis in rats and mice. (A) Ir-CPI at the indicated doses was administered i.v. 5 min before induction of 
thrombosis by 10% FeCl3 and complete stasis. The control group received PBS () instead of Ir-CPI (). Each point represents the mean ± SEM for five or 
six animals. (B and C) Ir-CPI at the indicated doses was administered i.v. before IVC ligature. The control group received PBS instead of Ir-CPI. The throm-
bosed IVC fragments were harvested and weighed 24 h later. Results were expressed by dividing the thrombus weight with mouse weight (mg/g; B) or 
thrombus length (mg/mm; C). (D and E) Time-course experiments of clot formation. Results were expressed by dividing the thrombus weight with mouse 
weight (mg/g; D) or thrombus length (mg/mm; E). The experiment shown in A is representative of two independent experiments. The data shown in  
B–E are presented as the mean ± SEM of at least four independent experiments. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (relative to vehicle); #, P ≤ 0.05  
(between 1 and 10 mg/kg Ir-CPI dose).JEM VOL. 206, October 26, 2009 
ARTICLE
2389
amount of thrombin generated or the kinetics of the process. 
Moreover, in this test, a large and physiologically irrelevant 
excess of activator is used, leading to a massive activation 
of the coagulation cascade. Consequently, effective inhibitor 
concentrations must usually be relatively high. The results 
obtained with Ir-CPI confirm that this protein is a potent in-
hibitor of thrombin generation.
Contact phase defects are manifested by a prolongation of 
aPTT in vitro. However, deficiencies affecting these factors 
do not cause excessive bleeding (Colman, 1984). As an excep-
tion to this rule, FXI deficiency leads to mild bleeding after 
trauma or injury. This is in agreement with the suggestion that 
the main role of FXI is not the initiation of coagulation but 
the insurance of a positive-feedback mechanism ensuring the 
secondary production of thrombin, which is essential for effi-
cient hemostasis (Gailani and Broze, 1991). A thrombophilia 
study confirmed this hypothesis. It showed that an increased 
level of FXI is a risk factor for thrombosis. It also suggested 
that FXI had a twofold role: secondary generation of throm-
bin and down-regulation of fibrinolysis via TAFI (Meijers   
et al., 2000). The ability of thrombin to activate FXI may also 
explain why FXII is not required for normal blood clotting in 
Likewise, by binding to FXIa, Ir-CPI prevents both activa-
tion of FXII into FXIIa and activation of FIX into FIXa. 
Moreover, Ir-CPI also has an affinity for kallikrein (Table I) 
so that it has an inhibitory effect on the kallikrein–kinin sys-
tem as well as an immediate inhibitory effect on activation of 
FXII into FXIIa. Thus, the specificity of Ir-CPI for the acti-
vated factors initiating the contact phase alone is remarkable 
in that it only targets the contact phase during activation.
To better evaluate the potential anticoagulant effect of   
Ir-CPI in human plasma, we used the recently described throm-
bin generation method as a pharmacological tool (Robert   
et al., 2009). Thrombin generation, which is more sensitive 
to the action of anticoagulant (Prasa et al., 1997a,b), has long 
been known to be a valid physiological function test for in-
vestigating thrombin activity during the coagulation process 
(MacFarlane and Biggs, 1953; Pitney and Dacie, 1953). This 
test has major advantages in comparison with the classical PT 
or aPTT clotting assays. Only the initiation phase is investi-
gated in the latter assay and its endpoint is plasma clotting, 
which occurs when the burst of thrombin generation has not 
yet taken place (Mann et al., 2003). Measurement of PT or 
aPTT therefore provides no information about the total 
Table III.  Hemostasis and coagulation in Ir-CPI treated mice
Inhibitors aPTT PT Fibrinolysis Bleeding effect (O.D. 450 nm)
s s min
PBS 21.7 ± 2.4 25.4 ± 1.6 26 ± 9.7 8.6 ± 3.3
Ir-CPI 1 mg/kg 25.8 ± 5.8 25.1 ± 0.1 25 ± 11.3 7.6 ± 4.7
Ir-CPI 10 mg/kg 39.8 ± 5.2a 27.5 ± 2.6 21 ± 4.6 14.5 ± 4.8
LMWH 0.5 mg/kg 47.5 ± 6.3a 28.9 ± 3.3 23 ± 5.0 >30.0 ± 0.0a
Values are mean ± SEM (n = 5 for each test). LMWH, low molecular weight heparin.
aP < 0.05, as compared to values observed in the control (PBS) by one-way ANOVA and Student’s t test–Newman-Keuls test.
Figure 7.  Intravital microscopy images from mouse dorsal skinfold window chambers illustrating the effect of Ir-CPI on high light inten-
sity–induced thrombosis. (A) Representative images of microvessels of 1-mg/kg Ir-CPI–treated (bottom) and untreated (top) mice. The vessels after in-
jection of 10 mg/kg of rose bengal but before high light intensity stimulation (time, 0) are shown on the left. The same vessels 2 h after high light 
intensity excitation (time, 2 h) are shown on the right. Representative images of five experiments are shown. Bars, 100 µm. (B) Bar graph showing 
changes in blood flow velocity in untreated and Ir-CPI–treated mice (n = 5). Results are expressed as a percentage of initial flow measured in each vessel. 
Data represent the mean ± SEM of results obtained from five independent experiments. **, P < 0.01.2390 Ir-CPI, A NOVEL ANTITHROMBOTIC FACTOR | Decrem et al.
Ir-CPI acts mainly on clot propagation. This observation is 
consistent with the in vitro interactions of Ir-CPI with FXIIa, 
FXIa, and kallikrein, with these contact factors being mainly 
implicated in the clot propagation. The change in thrombus 
weight and density is probably related to the inhibitory effect 
of Ir-CPI on thrombin generation. Furthermore, the inhibi-
tory effect of Ir-CPI on thrombus formation in the mouse 
model shows the efficacy of Ir-CPI over a 24-h period, con-
firming the results obtained in the rat showing the presence 
of 41% of Ir-CPI 24 h after its i.v. injection. From the 
point of view of clotting physiology, the ex vivo values of 
aPTT, PT, and fibrinolysis times were unchanged at an Ir-CPI 
concentration of 0.1 mg/kg. At higher doses (1 mg/kg and 
10 mg/kg), only the value of aPTT was significantly increased 
as it was observed with FXII-KO mice (Renné et al., 2005). 
Importantly, it should also be pointed out that the bleeding 
time of animals treated by Ir-CPI was not significantly changed 
even at the highest doses.
In the arterial model, thrombosis was induced by i.v. in-
jection of rose bengal followed by high light intensity exposi-
tion. In Ir-CPI–treated mice, no changes in the arterioles’ 
aspect or flow could be recorded after 2 h (Fig. 7 A) or after 
24 h (not depicted). In addition, we observed a flow reduc-
tion in the control mice, whereas in Ir-CPI-treated mice, the 
flow velocity remained unchanged. Therefore, in these in 
vivo models used to study platelet recruitment and thrombus 
formation at sites of arteriole injury in Ir-CPI–treated mice, 
we observed a profound defect in the formation and stabiliza-
tion of platelet-rich thrombi.
Although contact phase factors have long been consid-
ered to not be required for in vivo coagulation, recent studies 
show that mice genetically deprived of one of these factors 
are protected against the formation of both venous and arte-
rial thrombi (Renné et al., 2005). Results obtained with the 
Ir-CPI protein confirm that a specific coagulation contact 
phase inhibitor is effective in animal thromboembolic mod-
els. Therefore, our study confirms the important role of con-
tact phase factors in the coagulation propagation phase that 
causes the secondary generation of active thrombin. How-
ever, results obtained with the Ir-CPI protein do not exclude 
the possibility that the effects observed in vivo may result 
from the reciprocal inhibition of contact phase factors. These 
results could be the result of FXIa inhibiting the activation of 
FIX in the amplification phase, depending on the former’s 
activation by thrombin.
The  selection  of  anticoagulant  therapy,  whether  for 
venous thromboembolism or arterial thrombosis (myocardial 
infarction or stroke), is based on how well the drug inhibits 
thrombosis and on the extent of the bleeding side effects 
(Colman, 2006). The discovery that FXII deficiency protects 
against thrombosis without causing spontaneous bleeding 
makes FXII a unique and attractive target for drug design 
(Gailani and Renné, 2007; Renné and Gailani, 2007). The 
data of the current study demonstrate that an exogenous mol-
ecule targeting the contact phase factors (FXII and FXI) can 
protect against the formation of a thrombus without altering 
vivo as shown in patients deficient for FXII. Similarly, Renné 
et al. (2005) showed that the coagulation balance of FXII KO 
mice is not disturbed in any way and is similar to that observed 
in wild-type mice. However, FXII KO mice are protected 
from thrombus formation, an essential element in venous and 
arterial thrombosis. In FXI-deficient mice, fibrin formation in 
ischemic vessels in the brain is reduced in comparison with 
wild-type mice, suggesting that the thrombosis-inducing ef-
fects of FXII are mediated through FXI and the contact phase 
(Renné et al., 2005, 2006; Colman, 2006; Kleinschnitz et al., 
2006). Moreover, a recent study indicates that, in a plasma 
environment, thrombin or TF do not activate FXI, even in 
the presence of platelets (Pedicord et al., 2007). These results, 
together with the identification of an antithrombotic pheno-
type in FXII KO mice, suggest that FXI activation by the 
contact system may be physiologically relevant. Although dif-
ferences may exist between mouse and human systems, FXII 
or FXI probably have similar roles during thrombosis in mice 
and in humans. These proteases may, therefore, provide at-
tractive targets for the prevention or treatment of thrombo-
embolic diseases with a minimal risk of therapy-associated 
bleeding  (Gailani  and  Renné,  2007;  Renné  and  Gailani, 
2007). Kleinschnitz et al. (2006) used a synthetic inhibitor of 
FXIIa (Silverberg and Kaplan, 1982), d-Pro-Phe-Arg-CH2Cl 
(PCK), to highlight FXIIa as a new drug target. However, the 
selectivity of this compound should be challenged. Indeed, it 
also inhibits in vitro the amidolytic activity of plasma kalli-
krein, plasmin, factor Xa, thrombin, TF/FVIIa, and uroki-
nase. Moreover, the peptidic structure, as well as the alkylating 
behavior of the chloromethyl function, makes PCK unsuited 
for oral clinical use as anticoagulant agent (Kettner and Shaw, 
1978; Robert et al., 2008).
We therefore evaluated the inhibitory effect of Ir-CPI on 
both venous and arterial thrombus formation in animal mod-
els closer to physiological venous and arterial thrombus for-
mation. In venous models, thrombosis was induced by the 
infusion of a mixture of collagen and epinephrine into the 
jugular vein of the mouse, by ferric chloride and complete 
stasis of the posterior vena cava in the rat, and by complete 
stasis of the vena cava for 24 h in the mouse. Consistent with 
the results obtained with FXII-deficient mice (Renné et al., 
2005), Ir-CPI seems to protect against collagen/epinephrine 
thromboembolism (20 and 26.7% of survivors at a dose of   
1 and 10 mg/kg of Ir-CPI, respectively) without any effect on 
primary hemostasis, confirming that Ir-CPI does not inhibit 
the platelet adhesion/activation and aggregation processes. In 
the two other venous models, it was also shown that Ir-CPI 
reduced thrombus formation in a dose-dependant manner 
with an EC50 calculated in the rat of 50 µg/kg and a maxi-
mum effect starting from 0.1 mg/kg (mean reduction of 71.0 ± 
5.1% in the weight of the clot). Moreover, the clot weight/
body weight ratio and the clot weight/clot length ratio were 
significantly lower in Ir-CPI–treated mice at a dose of 1 mg/kg 
than in untreated mice after 6, 16, and 24 h of stasis, whereas 
no difference was observed after 2 and 4 h, showing that 
Ir-CPI also impacts clot density. These data suggest that JEM VOL. 206, October 26, 2009 
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dition of an agonist (collagen; Chrono-Log Corporation). Platelet aggregation 
was measured as the maximal per 10-min change in impedance.
Anticoagulant activity
The anticoagulant activities of Ir-CPI were determined by four coagulation 
tests using a Start8 coagulometer (Diagnostica Stago). Blood samples were 
collected in 3.8% trisodium citrate from healthy human donors, rats, and 
mice. Platelet-poor plasma (PPP) was obtained by further centrifugation at 
4,000 g for 10 min.
aPTT. 25 µl of plasma and 25 µl Ir-CPI were preincubated for 2 min at 
37°C. Mixtures were activated for 4 min with 25 µl actin FS (Siemens). 
Clotting was initiated by adding 50 µl of 25 mM CaCl2.
PT. 25 µl of plasma and 25 µl Ir-CPI were preincubated for 2 min at 37°C. 
Mixtures were activated for 4 min with 25 µl innovin, 1/10 from human 
plasma or 1/100 from animal plasma (Siemens). The clotting reaction was 
started by adding 50 µl of 25 mM CaCl2.
Russel viper venom time. 25 µl of plasma, 50 µl Hepes buffer (25 mM 
Hepes, 2% Glycine, and 145 mM NaCl, pH 7.35), and 25 µl Ir-CPI were 
preincubated for 2 min at 37°C. Clotting was initiated by the addition of   
25 µl LA 1 (Siemens).
Thrombin time 25 µl of plasma, 50 µl Hepes buffer, and 25 µl Ir-CPI were 
preincubated for 2 min at 37°C. Clotting was initiated by the addition of   
25 µl thrombin (Diagnostica Stago).
Determination of clot lysis times
Clot lysis times on PPP were determined as previously described (Boudjeltia 
et al., 2002).
Thrombin activity profiles
Materials. PPP reagent (5 pM TF and 4 µM PL in the final mixture), PPP 
LOW reagent (1 pM TF and 4 µM PL in the final mixture), and thrombin 
calibrator were purchased from Synapse BV. For each experiment, a fresh 
mixture of fluorogenic substrate/calcium chloride buffer solution was pre-
pared as follows: 2,275 µl of buffer (20 mM Hepes, pH 7.35) containing 
60 mg/ml of bovine serum albumin (Sigma-Aldrich) and 240 µl of 1 M calcium 
chloride were mixed with 60 µl of 100 mM DMSO solution of fluorogenic 
thrombin substrate (Z-Gly-Gly-Arg-AMC; Bachem). Actin FS was diluted 
25-fold with distilled water.
Preparation of human plasma. Blood from healthy male volunteers, who 
were free from medication for at least 2 wk, was taken by venipuncture and 
collected into 0.105 M sodium citrate (9:1 vol/vol). PPP was obtained by 
centrifugation at room temperature for 10 min at 2,500 g and was used im-
mediately after centrifugation.
Calibrated  automated  thrombin  activity  measurement. Thrombin 
activity measurement was performed using the previously reported CAT 
procedure (Hemker et al., 2003; Robert et al., 2009). In brief, 80 µl PPP, 
10 µl PBS or Ir-CPI, and 20 µl PPP reagent, PPP LOW reagent, or diluted 
Actin FS were mixed in a 96-well microtiter plate (Immulon 2HB; Thermo 
Fisher Scientific) and incubated for 5 min at 37°C. The coagulation process 
was triggered by the addition of 20 µl of substrate/calcium chloride buffer at 
37°C. A calibration condition was also realized. In this latter case, the same 
protocol as that described using PBS was followed, but the activator was re-
placed by 20 µl of thrombin calibrator. The reaction of fluorogenic thrombin 
substrate hydrolysis was monitored on a microplate fluorometer (Fluoroskan 
Ascent FL; Thermo Fisher Scientific) with a 390/460-nm (excitation/emis-
sion) filter set. Fluorescence was measured every 20 s for 60 min. The com-
mercially available Thrombinoscope software (Synapse BV) automatically 
processed the acquired data to give thrombin activity profile curves and mea-
surement parameters (lag time and Cmax). 10 Ir-CPI concentrations ranging 
from 0.001 to 9.077 µM were tested in each experiment in triplicate.
coagulation  and  bleeding  times.  Effectively,  Ir-CPI  has  a 
dose-dependent protective action against thrombin-induced 
thromboembolism in four animal models without disturbing 
the clotting balance. At the effective doses, no effect was ob-
served on aPTT and PT values, fibrinolysis time, or, remark-
ably, on bleeding time. To our knowledge, this is the first 
time that an inhibitor of the coagulation contact phase has 
been shown to protect against the formation of venous and 
arterial thrombi. Ir-CPI may, therefore, provide an impor-
tant therapeutic tool by protecting patients at risk from dis-
eases such as pulmonary embolism, cerebral ischemia, deep 
vein, and arterial thrombosis.
MATERIALS AND METHODS
Animals
Animal care and experimental procedures were performed in accordance 
with the Helsinki Declaration (Publication 85–23, revised 1985), local insti-
tutional guidelines (laboratory license LA 1500474), and the Belgian law   
of 14th August 1986, as well as the royal decree of the 14th of November 
1993 on the protection of laboratory animals. Animal protocols were ap-
proved by the local ethic commission of the Université Libre de Bruxelles. 
Studies were performed using male Sprague-Dawley OFA rats weighing 
250–300 g (Harlan) and 8-wk-old NMRI female mice weighing 20–25 g 
(Elevage Janvier).
Expression and purification of recombinant Ir-CPI  
in Escherichia coli
The coding region of Ir-CPI cDNA was cloned in frame with GST in the 
pGEX-6P-1 vector and transformed into E. coli strain BL21. Production of 
the recombinant protein was induced by the addition of 1 mM IPTG at 
37°C for 2 h. After centrifugation of bacterial lysates prepared using a French 
press, the resulting supernatant, which contained the GST-Ir-CPI fusion 
protein, was incubated with Glutathione Sepharose High Performance (GE 
Healthcare). Ir-CPI was released by cleaving with PreScission protease ac-
cording to the manufacturer’s specifications and then purified to homogene-
ity by gel filtration chromatography using a HiLoad Superdex 75 column 
(GE Healthcare). Purified proteins were then tested for endotoxin contami-
nation using the Limulus Amebocyte Lysate QCL-1000 kit (Cambrex). En-
dotoxin levels were <0.4 enzyme units/mg of protein in all preparations 
used. Samples containing endotoxin amounts superior to that threshold were 
loaded on Detoxi-Removal endotoxin gel columns according to the manu-
facturer’s instructions (Thermo Fisher Scientific) to ensure the removal of 
endotoxins. This was followed by dialysis against buffers appropriate for the 
subsequent experiments. Protein concentrations in the endotoxin-purified 
batches were determined using a Micro BCA kit (Thermo Fisher Scientific) 
according to the manufacturer’s instructions.
Primary hemostasis
Human blood samples were collected from healthy donors in 0.102-M triso-
dium citrate tubes (9:1 vol/vol). Global platelet function was measured on a 
PFA-100 machine (Siemens) with a collagen/epinephrine or collagen/ADP 
cartridge. The sample (1/10 protein in HBSS and 9/10 citrated whole blood) 
was aspirated through a capillary under steady high shear rates within 45 min 
of sample collection. Platelet plug formation was induced by the presence of 
the platelet agonists and the high shear rates, and this gradually occluded the 
aperture. The closure time was considered to be the time required to obtain 
full occlusion of the aperture. This time is called the closure time (CT) and is 
measured in seconds. The test is therefore a combined measure of platelet 
adhesion and aggregation. Platelet aggregation was performed using the im-
pedance channel of a Whole Blood Lumi-Aggregometer (Chrono-Log 
Corporation; Ingerman-Wojenski and Silver, 1984). With this method, the 
electrical impedance between two fine electrodes immersed in the sample in-
creases with platelet coating and aggregation on these electrodes after the ad-2392 Ir-CPI, A NOVEL ANTITHROMBOTIC FACTOR | Decrem et al.
The kinetics of interactions between Ir-CPI and the four interacting factors 
were performed after a new immobilization of Ir-CPI. The quantity of Ir-CPI 
immobilized for measurements of kinetics was deliberately maintained at a low 
level (to 200 RU) to avoid the problems of limitation of the reaction by the 
process of mass transport. Independence with respect to differences in flow of 
the initial rate of connection, measured by linear regression at the start of the ki-
netics after injections of analytes with increasing flows (30–70 µl/min), con-
firmed that the reactions were not limited by such a process. Interaction kinetics 
were determined for each analyte, with six different concentrations (from 5 nM 
to 300 nM). Binding data were analyzed using BIA evaluation software to de-
termine the kinetic constants. The specificity of the reaction was evaluated using 
the GST protein (1,000 RU immobilized on the surface of the sensor chip) as 
negative control.
Determination of radioactivity of 125I–Ir-CPI in rat blood
125I-labeled Ir-CPI was prepared by iodination with [125I] sodium iodide in   
20 mCi/mg of protein, using IODO-BEADS Iodination Reagent (Thermo 
Fisher Scientific), according to the manufacturer’s instructions. Free iodide was 
removed by extensive gel filtration on Sephadex G10.
The in vivo distribution of 125I–Ir-CPI in rat blood was evaluated after i.v. 
administration. Samples containing 10 × 106 cpm were resuspended in 200 µl of 
PBS and administered to rats. Blood was collected after 3, 20, 40, or 60 h by 
cardiac puncture in 3.8% trisodium citrate. Plasma was obtained by centrifuga-
tion, and aliquots of 500 µl were placed in glass test tubes. Radioactivity was de-
termined in a gamma counter.
Ex vivo effect of Ir-CPI on aPTT, PT, and fibrinolysis
Ir-CPI was administered i.v. to rats and mice, and blood was collected after   
5 min by cardiac puncture in 3.8% trisodium citrate. PPP was obtained by cen-
trifugation at 4,000 g for 10 min. The aPTT, PT, and fibrinolysis times were 
measured using theses procedures.
Collagen/epinephrine-induced pulmonary thromboembolism
20–25-g C57BL/6J mice were anesthetized by i.p. injection of a mixture of   
80 mg/kg ketamine and xylazine (5 mg/kg). 1–10 mg/kg Ir-CPI or vehicle was 
injected in the iliac vein 5 min before challenge. A mixture of 0.8 mg/kg colla-
gen and 60 µg/kg epinephrine was then injected into the jugular vein. Platelet 
counts were determined by flow cytometry.
Histopathologic analyses
C57BL/6J mice were killed and lungs were fixed at 4°C for 24 h in buffered 4% 
formaldehyde. Tissues were dehydrated and embedded in paraffin, cut into 5-µm 
sections, and stained with Mayer’s hematoxylin and eosin (Sigma-Aldrich).
Complete stasis combined with vessel injury induced venous 
thrombosis model in the rat
Thrombus formation was induced by a combination of complete stasis and 
vessel injury by ferric chloride according to the modification of the method 
described by Peternel et al. (2005). Rats were anesthetized i.p. with 70 mg/kg 
pentobarbital sodium. The abdomen was opened by making an incision 
along the linea alba toward the sternum, followed by exposition of the pos-
terior vena cava. Surgical threads, 1 cm apart, were placed loosely around the 
vena cava beneath the renal veins and above the bifurcation of the iliac veins 
to form a snare. Complete stasis was induced in the posterior vena cava by 
tightening the downstream snare firmly around the posterior vena cava. Si-
multaneously, a piece of filter paper (0.3 × 0.8 cm) saturated with 10% wt/vol 
ferric chloride solution was applied to the external surface of the posterior 
vena cava caudally of the ligature for 10 min, 10 min after the removal of the 
filter paper, the upstream snare was firmly tightened around the posterior 
vena cava, and the rat was then euthanized. The ligated venous segment was 
excised and the thrombus was removed and immediately weighed after blot-
ting off excess blood. Results were expressed in milligrams of thrombus per 
kilogram of rat body weight. Ir-CPI (0.5–1,000 µg/kg, corresponding to 
2 nM to 4 µM) or vehicle were injected in the left femoral vena 5 min be-
fore the induction of the thrombus formation.
Assay of the inhibitory effect of Ir-CPI on coagulation factors
The inhibitory activity of Ir-CPI was examined on seven procoagulant 
serine proteases (plasma kallikrein, FXIIa, FXIa, FIXa, FXa, thrombin, and 
FVIIa) and two fibrinolytic serine proteases (t-PA and plasmin). Each serine 
protease was preincubated with Ir-CPI in a 1:5 molar ratio for 5 min at 
37°C, followed by the addition of the appropriate chromogenic substrate 
(final concentration 0.5 mM). Final concentrations in a total volume of 200 µl 
in 96-microwell plates were the following: 3 nM kallikrein/S-2302, 62.5 nM 
FXIIa/S-2302, 31.25 nM FXIa/S2366, 500 nM FIXa/Spectrozyme FIXa, 
10 nM FXa/S-2222, 35 nM thrombin/Spectrozyme TH, 100 nM FT-FVIIa/
Spectrozyme FVIIa, 35 nM t-PA/Spectrozyme t-PA, and 30 nM plasmin/
Spectrozyme PL. The kinetics of substrate hydrolysis were measured over   
20 min. Chromogenic substrates S-2302, S-2366, and S-2222 were supplied 
by Chromogenix, and Spectrozyme FIXa, TH, FVIIa, t-PA, PL were ob-
tained from American Diagnostica Inc.
Assay of the effects of Ir-CPI on contact system activation  
in plasma
The effects of Ir-CPI on the activation of the contact system in human plasma 
were assessed from the generation of activated contact factors (FXIa, FXIIa, 
and kallikrein). Human plasma was treated with acid to inactivate plasma serine 
protease inhibitors (De La Cadena et al., 1987) and then diluted 1:10 in buffer. 
50 µl of diluted plasma was incubated with 20 µl of various concentrations of 
Ir-CPI for 5 min and then activated with 5 µl aPTT reagent (actin FS). After 
10 min, a chromogenic substrate mixture at a final concentration of 0.5 mM 
and one or two inhibitors, 100 nM of Maize trypsin inhibitor or 50 µM kallis-
top, were added, and the amidolytic activity of the generated enzyme was de-
termined at 405 nm for 3, 10, and 30 min for kallikrein, factor XIIa, and factor 
XIa, respectively. Sets of added chromogenic substrate and inhibitors were the 
following: S-2366, kallistop, and CTI for FXIa assay; S-2302 and kallistop for 
FXIIa assay; and S-2302 and CTI for kallikrein assay.
Effect of Ir-CPI in a reconstituted system
A reconstitution assay of the kallikrein–kininogen–kinin system was per-
formed using purified coagulation factors (FXIIa and prekallikrein). 12.5 nM 
FXIIa was preincubated with Ir-CPI in Hepes buffer for 2 min at 37°C. 12.5 nM 
prekallikrein was added to the mixture, and then prekallikrein activation 
was started. After 10 min, chromogenic substrate S-2302 and CTI were 
added, and the increase in absorbance at 405 nm was recorded over 3 min. 
Reconstitution assays of the intrinsic coagulation pathway were performed 
using purified coagulation factors FXI/FXIa and FXII/FXIIa. The effect of 
Ir-CPI on the activation of FXI by FXIIa was tested by incubating 15 nM 
FXI, 60 nM FXIIa, and Ir-CPI for 10 min at 37°C. After incubation, sub-
strate S-2366 was added and the increase in absorbance was measured. The 
effect of Ir-CPI on the activation of FXII by FXIa was tested by incubating 
15 nM FXIa, 60 nM FXII, and Ir-CPI for 10 min at 37°C. After incubation, 
substrate S-2302 was added and the increase in absorbance was measured.
Binding analysis using surface plasmon resonance
The interaction between Ir-CPI and coagulation (HK, plasma prekallikrein, 
plasma kallikrein, FXII, FXIIa, FXI, FXIa, FIX, FIXa, FX, FXa, prothrom-
bin, thrombin, and FVIIa) or fibrinolytic (t-PA, plasminogen, and plasmin) 
factors was monitored using a BIAcore X instrument (GE Healthcare). 15 µM 
Ir-CPI was immobilized on the surface of a CM5 sensor chip in 10 mM 
acetate buffer, pH 5.0, by the amine coupling procedure according to the 
manufacturer’s instructions. 1,500 RU of immobilized Ir-CPI were used for 
the assay. To subtract the nonspecific component from the apparent binding 
response, a blank flow cell was prepared using the same immobilizing proce-
dure without Ir-CPI. Binding analyses were performed using HBS buffer 
(10 mM Hepes, 150 mM NaCl 3 mM, and EDTA, pH 7.4, with 0.005% 
surfactant P20) as running buffer at 25°C. 100 µl of each 100-nM analyte 
was injected on the sensor chip at a flow rate of 70 µl/min. Association was 
monitored during an 84-s injection of analyte. Dissociation was monitored 
for 3 min after return to the running buffer. Regeneration of the sensor chip 
surface was achieved with a 15-µl pulse injection of 25 mM NaOH.JEM VOL. 206, October 26, 2009 
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treated mouse before thrombosis induction. Video 4 shows a real-time 
microscopy video of microvessels of an Ir-CPI–treated mouse 2 h after 
thrombosis induction. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20091007/DC1.
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